blaVIM-2 gene detection in metallo-β-lactamase-producing Pseudomonas aeruginosa strains isolated in an Intensive Care Unit in Ciudad Bolívar, Venezuela;Detección del gen blaVIM-2 en cepas de Pseudomonas aeruginosa productoras de metalo β-lactamasa aisladas en una unidad de cuidados intensivos en Ciudad Bolívar, Venezuela

Revista Chilena de Infectologia

Volumn 26, Issue 4, 2009, Pages 336-341

  Guevara, Armando ^a,b   de Waard, Jacobus ^c   Araque, María ^b  

^a UNIVERSIDAD DE ORIENTE   (Venezuela)

^b UNIVERSIDAD DE LOS ANDES   (Venezuela)

^c INSTITUTO DE BIOMEDICINA   (Venezuela)

Author keywords

BlaVIM 2 gene; Metallo lactamases,; Nosocomial infections; Pseudomonas aeruginosa

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; VIM 2 BETA LACTAMASE; VIM-2 BETA-LACTAMASE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BIOSYNTHESIS; CHILD; CROSS INFECTION; DISK DIFFUSION; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; INTENSIVE CARE UNIT; MALE; MICROBIOLOGY; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; VENEZUELA;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PHENOTYPE; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VENEZUELA; YOUNG ADULT;

EID: 70350050379     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. McGowan J E. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Med 2006; 119 (6 Suppl 1): S29-S36.
2. Rossolini G M. Acquired metallo-β-lactamases: an increasing clinical threat. Clin Infect Dis 2005; 41: 1557-8.
3. Walsh T R, Toleman M A, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18: 306-25.
4. Kimura S, Alba J, Shiroto K, Sano R, Niki Y, Maesaki S, et al. Clonal diversity of metallo-β-lactamase-possessing Pseudomonas aeruginosa in geographically diverse regions of Japan. J Clin Microbiol 2005; 43: 458-61.
5. Mendes R E, Castanheira M, García P, Guzmán M, Toleman M A, Walsh T R, et al. First isolation of bla (VIM-2) in Latin America: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 2004; 48: 1433-4.
6. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing:sixteenth informational supplement. M100-S16. Wayne (PA), USA: 2006.
7. Lee K, Lim Y S, Yong D, Yum J H, Chong Y. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp and Acinetobacter spp. J Clin Microbiol 2003; 41: 4623-9.
8. Gales A C, Menezes L C, Silbert S, Sader H S. Dissemination in distinct Brazilian regions of an epidemic carbapenem-resistant Pseudomonas aeruginosa producing SPM metallo-β-lactamase. J Antimicrob Chemother 2003; 52: 699-702.
9. Senda K, Arakawa Y, Ichiyama S, Nakashima K, Ito H, Ohsuka S, et al. PCR detection of metallo-β-lactamase gene (blaIMP) in gram-negative rods resistant to broad-spectrum β-lactams. J Clin Microbiol 1996; 34: 2909-13.
10. Tsakris A, Pournaras S, Woodford N, Palepou M F, Babini GS, Douboyas J, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 2000; 38: 1290-2.
11. Poirel L, Pitout J D, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiol 2007; 2: 501-12.
12. Fujimura S, Nakano Y, Sato T, Shirahata K, Watanabe A. Relationship between the usage of carbapenem antibiotics and the incidence of imipenem-resistant Pseudomonas aeruginosa. J Infect Chemother 2007; 13: 147-50.
13. Corvec S, Poirel L, Espaze E, Giraudeau C, Drugeon H, Nordmann P. Long-term evolution of a nosocomial outbreak of Pseudomonas aeruginosa producing VIM-2 metallo-enzyme. J Hosp Infect 2008; 68: 73-82.
14. Cornaglia G, Akova M, Amicosante G, Cantón R, Cauda R, Docquier J, et al. Metallo-β-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents 2007; 29: 380-8.
15. Hocquet D, Berthelot P, Roussel-Delvallez M, Favre R, Jeannot K, Bajolet O, et al. Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob Agents Chemother 2007; 51: 3531-6.
16. Nordmann P, Naas T, Fortineau N, Poirel L. Superbugs in the coming new decade; multi-drug resistance and prospects for treatment of Staphylococcus aureus, Enterococcus spp and Pseudomonas aeruginosa in 2010. Curr Opin Microbiol 2007; 10(5): 436-40.
17. Viana Vieira V, Lourenço da Fonseca E, Paulo Vincente A C. Metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in Brazil. Clin Microbiol Infect 2005; 11: 937.
18. Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infect 2004; 57: 112-18.
19. Walsh F, Bracher S, Turner P, Amyes S. Preferential selection of IMP and VIM metallo-β-lactamases by imipenem in Pseudomonas aeruginosa. Chemotherapy 2007; 53: 407-9.
20. Ministerio del Poder Popular para la Salud. Comite Terapéutico Nacional. Formulario terapéutico nacional. Disponible en: http://www.sefar.gob.ve/index_1/manual_terap_1.htm [Acceso 2 de febrero de 2008].